Plagued by production issues, Pfizer aims to shift EpiPen work to Mylan-Upjohn merger
Mylans EpiPen has had a troubled few yearsóto say the leastówith federal prosecutors knocking at the door and shortages plaguing production. Now, with Mylan and Pfizers generic business Upjohn working on a merger, a new EpiPen manufacturer could be in the cards.
Mylan and Pfizer are in talks to move EpiPens production to the new merged generics company, which is expected to take flight in mid-2020. A spokeswoman for Pfizer, which manufactures the drug under its Meridian Medical Technologies unit, said talks are ongoing and terms have yet to be finalized.